Casi Pharmaceuticals Stock Performance
| CASI Stock | USD 0.99 0 0.36% |
The firm shows a Beta (market volatility) of 1.55, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CASI Pharmaceuticals will likely underperform. At this point, CASI Pharmaceuticals has a negative expected return of -0.38%. Please make sure to confirm CASI Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if CASI Pharmaceuticals performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CASI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:10 | Last Split Date 2022-06-02 |
1 | Foresite Capital Management VI LLC Sells 542,262 Shares of CASI Pharmaceuticals Inc. CASI | 11/25/2025 |
2 | CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting | 12/08/2025 |
3 | CASI Pharmaceuticals wins Nasdaq extension to meet listing rules - MSN | 12/26/2025 |
4 | Will CASI Pharmaceuticals Inc. stock benefit from AI adoption - Market Risk Analysis Risk Managed Investment Strategies - ulpravda.ru | 01/08/2026 |
5 | 12 Health Care Stocks Moving In Wednesdays After-Market Session - Benzinga | 01/14/2026 |
6 | CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejecti... | 01/15/2026 |
7 | Is Alkermes Outperforming Other Medical Stocks This Year | 02/02/2026 |
| Begin Period Cash Flow | 17.1 M | |
| Total Cashflows From Investing Activities | 11.2 M |
CASI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 135.00 in CASI Pharmaceuticals on November 5, 2025 and sell it today you would lose (36.00) from holding CASI Pharmaceuticals or give up 26.67% of portfolio value over 90 days. CASI Pharmaceuticals is currently does not generate positive expected returns and assumes 5.4146% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than CASI, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CASI Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of CASI Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.99 | 90 days | 0.99 | about 61.25 |
Based on a normal probability distribution, the odds of CASI Pharmaceuticals to move above the current price in 90 days from now is about 61.25 (This CASI Pharmaceuticals probability density function shows the probability of CASI Stock to fall within a particular range of prices over 90 days) .
CASI Pharmaceuticals Price Density |
| Price |
Predictive Modules for CASI Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CASI Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CASI Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CASI Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. CASI Pharmaceuticals is not an exception. The market had few large corrections towards the CASI Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CASI Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CASI Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.65 | |
β | Beta against Dow Jones | 1.55 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | -0.12 |
CASI Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CASI Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CASI Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| CASI Pharmaceuticals generated a negative expected return over the last 90 days | |
| CASI Pharmaceuticals has high historical volatility and very poor performance | |
| CASI Pharmaceuticals has some characteristics of a very speculative penny stock | |
| CASI Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 28.54 M. Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 9.61 M. | |
| CASI Pharmaceuticals currently holds about 24.57 M in cash with (29.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Is Alkermes Outperforming Other Medical Stocks This Year |
CASI Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CASI Stock often depends not only on the future outlook of the current and potential CASI Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CASI Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.3 M | |
| Cash And Short Term Investments | 16.1 M |
CASI Pharmaceuticals Fundamentals Growth
CASI Stock prices reflect investors' perceptions of the future prospects and financial health of CASI Pharmaceuticals, and CASI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CASI Stock performance.
| Return On Equity | -10.94 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (1.84) % | ||||
| Operating Margin | (3.33) % | ||||
| Current Valuation | 34.51 M | ||||
| Shares Outstanding | 20.55 M | ||||
| Price To Earning | (16.46) X | ||||
| Price To Book | 11.21 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 28.54 M | ||||
| Gross Profit | 9.61 M | ||||
| EBITDA | (34.87 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 24.57 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 22.14 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | (1.39) X | ||||
| Cash Flow From Operations | (29.22 M) | ||||
| Earnings Per Share | (3.02) X | ||||
| Market Capitalization | 20.96 M | ||||
| Total Asset | 53.67 M | ||||
| Retained Earnings | (700.08 M) | ||||
| Working Capital | 3.12 M | ||||
| Current Asset | 17.15 M | ||||
| Current Liabilities | 3.51 M | ||||
About CASI Pharmaceuticals Performance
By evaluating CASI Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into CASI Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CASI Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CASI Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 99.21 | 144.18 | |
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (2.07) | (1.97) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (19.09) | (18.13) |
Things to note about CASI Pharmaceuticals performance evaluation
Checking the ongoing alerts about CASI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CASI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CASI Pharmaceuticals generated a negative expected return over the last 90 days | |
| CASI Pharmaceuticals has high historical volatility and very poor performance | |
| CASI Pharmaceuticals has some characteristics of a very speculative penny stock | |
| CASI Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 28.54 M. Net Loss for the year was (39.26 M) with profit before overhead, payroll, taxes, and interest of 9.61 M. | |
| CASI Pharmaceuticals currently holds about 24.57 M in cash with (29.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Is Alkermes Outperforming Other Medical Stocks This Year |
- Analyzing CASI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CASI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining CASI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CASI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CASI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CASI Pharmaceuticals' stock. These opinions can provide insight into CASI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CASI Stock analysis
When running CASI Pharmaceuticals' price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |